Payment overview · 2025
General Payments
$207.66
12 reported records · 9 companies
Healthcare provider profile · identity verified
Samuel Jackson Dail, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW BERN, NC · NPI 1255710331
Verified facts
What the public records show
CMS Open Payments records show Samuel Jackson Dail, M.D. received $207.66 in general payments during 2025 across 12 reported records.
GlaxoSmithKline, LLC. accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.12 | 21.7% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $40.17 | 19.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.15 | 11.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.05 | 9.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.49 | 8.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.52 | 8.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.26 | 7.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.21 | 6.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.69 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $207.66 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.12 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $40.17 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
63 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 433 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 290 | 59 |
| Metformin Hcl | Metformin Hcl | 283 | 75 |
| Lisinopril | Lisinopril | 251 | 67 |
| Losartan Potassium | Losartan Potassium | 227 | 63 |
| Omeprazole | Omeprazole | 224 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 34 |
| Allopurinol | Allopurinol | 121 | 26 |
| Furosemide | Furosemide | 113 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 17 |
| Simvastatin | Simvastatin | 108 | 26 |
| Gabapentin | Gabapentin | 107 | 31 |
| Jardiance | Empagliflozin | 105 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 24 |
| Trazodone Hcl | Trazodone Hcl | 100 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 24 |
| Potassium Chloride | Potassium Chloride | 95 | 21 |
| Ozempic | Semaglutide | 93 | 19 |
| Alendronate Sodium | Alendronate Sodium | 88 | 24 |
| Prednisone | Prednisone | 84 | 57 |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 18 |
| Glimepiride | Glimepiride | 67 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 27 |
| Ramipril | Ramipril | 64 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 63 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 47 |
| Tramadol Hcl | Tramadol Hcl | 62 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 11 |
| Meloxicam | Meloxicam | 59 | 16 |
| Atenolol | Atenolol | 55 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 15 |
| Telmisartan | Telmisartan | 52 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 12 |
| Lorazepam | Lorazepam | 49 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 16 |
| Verapamil Er | Verapamil Hcl | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Carvedilol | Carvedilol | 41 | 12 |
| Finasteride | Finasteride | 41 | 11 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 40 | 40 |
| Diazepam | Diazepam | 39 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 37 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Glipizide | Glipizide | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 30 |
| Celecoxib | Celecoxib | 30 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 15 |
| Meclizine Hcl | Meclizine Hcl | 30 | 13 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Naproxen | Naproxen | 30 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 22 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 28 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Indapamide | Indapamide | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 14 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Valacyclovir | Valacyclovir Hcl | 21 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Baclofen | Baclofen | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Temazepam | Temazepam | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $207.66 · 12 records | GlaxoSmithKline, LLC. | Auvelity, INCEPTIV, JATENZO, NURTEC ODT, TRELEGY ELLIPTA, TRINTELLIX, Tymlos, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error